Pallavi Kumar

pallavi-p-kumarPallavi Kumar, MD, is a medical oncologist at MedStar Franklin Square Medical Center, where she specializes in melanoma and gastrointestinal and gynecologic malignancies. Dr. Kumar also is an instructor of medicine in the Department of Internal Medicine at Johns Hopkins University.

Prior to joining MedStar, Dr. Kumar was director of the Gynecologic Tumor Program at Sinai Hospital of Baltimore. At MedStar Franklin Square, Dr. Kumar is a member of the Risk Management Committee, the Advisory Board for the Development of the Oncology Program, and the Data Monitoring and Safety Committee. She received the Johns Hopkins University/Sinai Hospital Award for Excellence in Professionalism and Humanism. She has served as principal investigator for 33 industry- and government-sponsored clinical trials.

Dr. Kumar has written book chapters and articles for peer-reviewed journals, including the Bethesda Handbook of Hematology, Journal of Clinical Oncology, and Hematology-Oncology Therapy. She has also spoken at symposiums and seminars, on topics including melanoma and genetic risk for cancer. Dr. Kumar is board certified in Oncology and Internal Medicine, and she is a member of the American Society of Clinical Oncology and the Gynecologic Oncology Group.

Dr. Kumar earned her medical degree from East Tennessee State University, Johnson City, TN. She continued her training with a residency in Internal Medicine at Johns Hopkins University/Sinai Hospital, Baltimore, MD, and a fellowship in Hematology and Oncology at the National Cancer Institute, Bethesda, MD.

Research Interests

Dr. Kumar’s research interests include

  • Gynecologic oncology
  • Melanoma
  • Gastrointestinal malignancies
  • Neuro-oncology
  • HIV-related malignancies

Selected Research

Randomized, phase 3 study of patients with advanced melanoma

Dr. Kumar is a principal investigator on the NRAS melanoma and MEK inhibitor (NEMO) trial. This randomized phase 3, open label, multicenter, two-arm study was designed to compare the efficacy of MEK162 versus Dacarbazine in patients with previously untreated advanced unresectable or metastatic NRAS mutation-positive melanoma. This trial is sponsored by Novartis Pharmaceuticals.

A multi-national, prospective, observational study in patients with unresectable or metastatic melanoma (IMAGE)

Dr. Kumar is a principal investigator on this clinical trial sponsored by Bristol-Myers Squibb. This study is designed to examine the use and safety of ipilimumab in the treatment of unresectable or metastatic melanoma.

View Dr. Pallavi's publications on PubMed

  • Research Areas
  • Oncology